Eccogene earns $50m as AstraZeneca starts Phase 3 weight-loss pill trials
Eccogene has received a $50 million milestone payment from AstraZeneca following the initiation of a global Phase 3 clinical program for elecoglipron. Elecoglipron is an investigational once-daily oral small-molecule GLP-1 receptor agonist being developed for cardiometabolic diseases, and the Phase
<p>Eccogene has received a $50 million milestone payment from AstraZeneca following the initiation of a global Phase 3 clinical program for elecoglipron. Elecoglipron is an investigational once-daily oral small-molecule GLP-1 receptor agonist being developed for cardiometabolic diseases, and the Phase </p>